Shenzhen listed Hubei Biocause Pharmaceutical has cancelled plans to merge with Guohua Life. Biocause currently hold a 51% stake in Guohua Life. The fundraising exercise to finance the acquisition of the remaining 41% stake was also aborted.
Please login to read the full news
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
Brought to you by